Ubs Asset Management Americas Inc Beam Therapeutics Inc. Transaction History

Ubs Asset Management Americas Inc

$446 Billion
Q3 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 1,665,385 shares of BEAM stock, worth $36.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,665,385

Previous 493,408 237.53%

Holding current value

$36.7 Million

Previous $8.39 Million 381.63%

% of portfolio

0.01%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$16.01 - $25.1 $18.8 Million - $29.4 Million	1,171,977 Added 237.53%	1,665,385 $40.4 Million
Q2 2025 Aug 14, 2025	BUY	$14.54 - $20.24 $797,940 - $1.11 Million	54,879 Added 12.51%	493,408 $8.39 Million
Q1 2025 May 19, 2025	BUY	$19.53 - $34.09 $832,153 - $1.45 Million	42,609 Added 10.76%	438,529 $8.56 Million
Q4 2024 Feb 14, 2025	SELL	$21.55 - $30.35 $115,637 - $162,858	-5,366 Reduced 1.34%	395,920 $9.82 Million
Q3 2024 Nov 14, 2024	SELL	$22.57 - $33.14 $412,647 - $605,898	-18,283 Reduced 4.36%	401,286 $9.83 Million

Q2 2024 Aug 13, 2024	BUY	$21.22 - $32.66 $2.57 Million - $3.96 Million	121,223 Added 40.63%	419,569 $9.83 Million
Q1 2024 May 15, 2024	SELL	$23.46 - $45.07 $173,252 - $332,841	-7,385 Reduced 2.42%	298,346 $9.86 Million
Q4 2023 Feb 14, 2024	BUY	$17.69 - $30.76 $452,439 - $786,717	25,576 Added 9.13%	305,731 $8.32 Million
Q3 2023 Nov 13, 2023	BUY	$23.01 - $32.46 $1.02 Million - $1.43 Million	44,132 Added 18.7%	280,155 $6.74 Million
Q1 2023 May 15, 2023	SELL	$30.15 - $48.79 $376,272 - $608,899	-12,480 Reduced 5.02%	236,023 $7.23 Million
Q4 2022 Feb 14, 2023	BUY	$36.73 - $51.6 $6.97 Million - $9.79 Million	189,713 Added 322.7%	248,503 $9.72 Million
Q3 2022 Nov 14, 2022	SELL	$39.79 - $70.31 $261,738 - $462,499	-6,578 Reduced 10.06%	58,790 $2.8 Million
Q2 2022 Aug 12, 2022	BUY	$29.86 - $62.36 $614,847 - $1.28 Million	20,591 Added 45.99%	65,368 $2.53 Million
Q1 2022 May 16, 2022	BUY	$53.73 - $82.16 $231,952 - $354,684	4,317 Added 10.67%	44,777 $2.57 Million
Q4 2021 Feb 14, 2022	BUY	$68.02 - $99.06 $55,776 - $81,229	820 Added 2.07%	40,460 $3.22 Million
Q3 2021 Nov 15, 2021	BUY	$84.37 - $133.6 $159,965 - $253,305	1,896 Added 5.02%	39,640 $3.45 Million
Q2 2021 Aug 16, 2021	BUY	$64.12 - $128.71 $1.26 Million - $2.52 Million	19,593 Added 107.94%	37,744 $4.86 Million
Q1 2021 May 14, 2021	BUY	$71.28 - $120.75 $364,454 - $617,394	5,113 Added 39.22%	18,151 $1.45 Million
Q4 2020 Mar 01, 2021	BUY	$22.24 - $95.63 $289,965 - $1.25 Million	13,038 New	13,038 $1.06 Million

Others Institutions Holding BEAM

# of Institutions

249

Shares Held

95M

Call Options Held

888K

Put Options Held

549K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.55B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Beam Therapeutics Inc. Transaction History